Invokana (canagliflozin) dosing, indications, interactions, adverse effects, and more (2023)

  • aliskiren

    aliskiren and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • amiloride

    amiloride and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • azilsartan

    azilsartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • benazepril

    benazepril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • betrixaban

    canagliflozin increases levels of betrixaban by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor.

  • candesartan

    candesartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • captopril

    captopril and canagliflozin both increase serum potassium. Use Caution/Monitor. Monitor potassium

  • carbamazepine

    carbamazepine decreases levels of canagliflozin by increasing metabolism. Use Caution/Monitor. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.

  • chlorpropamide

    chlorpropamide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • cyclosporine

    cyclosporine and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • digoxin

    canagliflozin increases levels of digoxin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Digoxin AUC and peak serum concentration increased when coadministered with canagliflozin.

  • drospirenone

    drospirenone and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • dulaglutide

    dulaglutide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • enalapril

    enalapril and canagliflozin both increase serum potassium. Use Caution/Monitor.

    (Video) Diabetes medications - SGLT2 inhibitors - Canagliflozin (Invokana)

  • eplerenone

    eplerenone and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • eprosartan

    eprosartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • finerenone

    canagliflozin and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.

  • fosinopril

    fosinopril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • glimepiride

    glimepiride, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • glipizide

    glipizide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • glyburide

    glyburide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • heparin

    heparin and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • insulin aspart

    insulin aspart, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin aspart protamine/insulin aspart

    canagliflozin, insulin aspart protamine/insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin degludec

    canagliflozin, insulin degludec.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin degludec/insulin aspart

    canagliflozin, insulin degludec/insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin detemir

    insulin detemir, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin detemir.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin glargine

    insulin glargine, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin glargine.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

    (Video) Invokana for Type II Diabetes

  • insulin glulisine

    insulin glulisine, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin glulisine.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin inhaled

    canagliflozin, insulin inhaled.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin isophane human/insulin regular human

    canagliflozin, insulin isophane human/insulin regular human.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin lispro

    insulin lispro, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin lispro.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin lispro protamine/insulin lispro

    canagliflozin, insulin lispro protamine/insulin lispro.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin NPH

    insulin NPH, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin NPH.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • insulin regular human

    insulin regular human, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin regular human.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • irbesartan

    irbesartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • letermovir

    letermovir will increase the level or effect of canagliflozin by unspecified interaction mechanism. Use Caution/Monitor. Monitor glucose concentrations.

  • lisinopril

    lisinopril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • lithium

    canagliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. Comment: SGLT2 inhibitors with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.

  • lonapegsomatropin

    lonapegsomatropin decreases effects of canagliflozin by Other (see comment). Use Caution/Monitor. Comment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents.

  • losartan

    losartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • moexipril

    moexipril and canagliflozin both increase serum potassium. Use Caution/Monitor.

    (Video) Canagliflozin - Indications | Dosage | Side Effects and Precautions | Medindia

  • nateglinide

    nateglinide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • olmesartan

    olmesartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • pentamidine

    pentamidine and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • perindopril

    perindopril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • phenobarbital

    phenobarbital decreases levels of canagliflozin by increasing metabolism. Use Caution/Monitor. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.

  • phenytoin

    phenytoin decreases levels of canagliflozin by increasing metabolism. Use Caution/Monitor. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.

  • potassium acid phosphate

    potassium acid phosphate and canagliflozin both increase serum potassium. Modify Therapy/Monitor Closely.

  • potassium chloride

    potassium chloride and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • potassium citrate

    potassium citrate and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • potassium citrate/citric acid

    canagliflozin and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.

  • potassium phosphates, IV

    potassium phosphates, IV and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • quinapril

    quinapril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • ramipril

    ramipril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • repaglinide

    repaglinide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

    (Video) Diabetes Medications - SGLT2 inhibitors - Canagliflozin and Metformin (Invokamet)

  • rifampin

    rifampin decreases levels of canagliflozin by increasing metabolism. Use Caution/Monitor. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.

  • ritonavir

    ritonavir decreases levels of canagliflozin by increasing metabolism. Use Caution/Monitor. Coadministration with potent UGT enzyme inducers: Consider increasing dose to 300 mg qDay if 100 mg/day tolerate and additional glycemic control required (eGFR must be >60 mL/min/1.73 m2 to increase dose); if eGFR <60 mL/min/1.73 m2, consider using a different antihyperglycemic agent.

  • sacubitril/valsartan

    sacubitril/valsartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • somapacitan

    somapacitan decreases effects of canagliflozin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. .

  • spironolactone

    spironolactone and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • succinylcholine

    succinylcholine and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • tacrolimus

    tacrolimus and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • telmisartan

    telmisartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • tolazamide

    tolazamide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • tolbutamide

    tolbutamide, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

  • trandolapril

    trandolapril and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • triamterene

    triamterene and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • trimethoprim

    trimethoprim and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • valsartan

    valsartan and canagliflozin both increase serum potassium. Use Caution/Monitor.

    (Video) Diabetes medications - SGLT 2 inhibitors

  • voclosporin

    voclosporin and canagliflozin both increase serum potassium. Use Caution/Monitor.

  • FAQs

    What is canagliflozin Invokana used for? ›

    Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).

    What are the side effects to Invokana? ›

    Mild side effects that have been reported with Invokana include:
    • yeast infection*
    • changes in urination, including: urgently needing to urinate more often than usual. producing more urine than usual. ...
    • urinary tract infection (UTI)
    • increased or excessive thirst.
    • dry mouth.
    • constipation.
    • nausea.
    • vaginal itching.

    What are contraindications for Invokana? ›

    Who should not take Invokana?
    • low blood sugar.
    • high levels of potassium in the blood.
    • chronic heart failure.
    • peripheral vascular disease.
    • decreased calcification or density of bone.
    • pregnancy.
    • decreased blood volume.
    • diabetic complication causing injury to some body nerves.

    How is Invokana dosed? ›

    Recommended Dosage

    100 mg orally once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily for additional glycemic control. 100 mg once daily.

    Is Invokana safe for kidneys? ›

    INVOKANA significantly reduced the rates of the primary composite outcome of end-stage kidney disease (ESKD), doubling of serum creatinine (dSCr), and renal or cardiovascular (CV) death (43.2 and 61.2 per 1000 patient years [PY] in the INVOKANA and PBO arms, respectively), resulting in a 30% relative risk reduction ( ...

    When is the best time to take Invokana? ›

    It is best to take INVOKANA before the first meal of the day. Your doctor may tell you to take INVOKANA along with other diabetes medicines. Low blood sugar can happen more often when INVOKANA is taken with certain other diabetes medicines.

    Can Invokana cause heart problems? ›

    Soukop placed Invokana's Hazard Ratio at 6.9, giving patients taking Invokana a significant increase in the risk of a cardiovascular event during the first 30 days of treatment. After the initial thirty days, those cardiovascular risks appeared to decrease.

    Why was Invokana taken off the market? ›

    Its reasoning was twofold: For one, while Invokana did elevate risks in trials, the FDA found on its second look that the risk was “lower than previously described,” particularly when patients are “appropriately monitored,” it said.

    Does Invokana cause neuropathy? ›

    Risk factors for Invokana amputations include:

    Also known as peripheral arterial disease, this condition reduces blood flow to the feet. Neuropathy. This nerve damage causes weakness, numbness and pain, especially in the hands and feet.

    Can canagliflozin cause kidney damage? ›

    Based on recent reports, we have revised the warnings in the drug labels to include information about acute kidney injury and added recommendations to minimize this risk. Patients should seek medical attention immediately if they experience signs and symptoms of acute kidney injury.

    Can Invokana raise blood sugar? ›

    Invokana works by blocking the reabsorption of glucose by the kidney and increasing glucose excretion through the urine, which then lowers your blood glucose levels.

    Does Invokana lower blood pressure? ›

    Although it's not a blood pressure medication, INVOKANA® may help you see lower systolic blood pressure—on average 3–5 mmHg. Results may vary by dose and when used alone or with metformin, sitagliptin, or insulin.

    What is the dosing for canagliflozin? ›

    100 mg once daily; increased if tolerated to 300 mg once daily if required, dose to be taken preferably before breakfast.

    Is Invokana better than metformin? ›

    Is Invokana better than metformin? Neither of the medications are better than the other. Different diabetes medicines will suit different patients, depending on the individual medical situation. It is up to the prescriber to decide which medication will be most beneficial to their individual patients.

    What are the benefits of Invokana? ›

    Invokana is a brand-name medication that treats Type 2 diabetes. It's an SGLT2 inhibitor that can be used alone or combined with other diabetes medications like metformin. It's been shown to lower blood sugar levels, help you lose weight, and lower the risk of worsening heart and kidney problems.

    Does Invokana make you tired? ›

    In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.8%, 2.2%, and 2.0% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively) and loss of strength or energy (i.e., asthenia) (0.6%, 0.7%, and 1.1% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively).

    Does Invokana dehydrate you? ›

    Dehydration. INVOKANA® can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension).

    What is a good substitute for Invokana? ›

    Alternatives to medications like Invokana include:
    • Sulfonylureas.
    • Biguanides.
    • Meglitinides.
    • Thiazolidinediones.
    • DPP-4 inhibitors.
    • Alpha-glucosidase inhibitors.

    Does Invokana help the heart? ›

    INVOKANA® (canagliflozin) is a prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have known cardiovascular disease.

    Does Invokana protect the heart? ›

    For people with type 2 diabetes and existing heart disease, Invokana has been officially approved by the FDA to reduce the risk of heart attack, stroke, and heart-related death.

    Does Invokana cause hair loss? ›

    Does Invokana cause hair loss, pancreatitis, or joint pain? No, this isn't likely. Hair loss and joint pain weren't reported in studies of Invokana.

    Does Invokana cause stroke? ›

    In patients with established CV disease, treatment with INVOKANA® reduced the combined risk of heart attack, stroke and CV death by 18 percent compared to placebo (events occurred in 34.1 vs. 41.3 participants, respectively, per 1000 patient-years; HR: 0.82; 95 percent CI: 0.72 to 0.95).

    Can Invokana cause blood clots? ›

    Thromboembolic events: There are reports of patients succumbing to thromboembolic events after taking Invokana. A thromboembolic event is where blood clots form and travel to the vital organs, such as the heart, lungs or brain.

    Does Invokana make you urinate more? ›

    Invokana is prescription medication that treats Type 2 diabetes. It can also lower the risk of worsening kidney and heart problems and help you lose weight. Like all medications, Invokana can cause side effects. These include yeast infections, UTIs, and a more frequent need to pee.

    Is there a lawsuit against Invokana? ›

    Victims of Invokana genital gangrene may be entitled to compensation for their losses. Contact an Invokana lawyer if you believe that you suffered injuries resulting from your SGLT-2 inhibitor medication. Invokana lawyers are currently filing SGLT-2 lawsuits against the manufacturers of these drugs.

    Which is better Jardiance or Invokana? ›

    Invokana (canagliflozin) can be used together with other diabetes medicines to help lower your blood sugar, but it can be expensive because it's brand name. Lowers blood sugar. Jardiance (empagliflozin) lowers blood sugar for people with diabetes, but can increase the chance of a yeast infection.

    Is Invokana back on the market? ›

    Currently, Invokana is still on the market. The FDA did in 2017 regarding the increased risk of lower limb amputations in patients with established cardiovascular disease.

    Can canagliflozin cause amputations? ›

    Conclusions The increase in rate of amputation with canagliflozin was small and most apparent on an absolute scale for adults aged 65 or older with baseline cardiovascular disease, resulting in a number needed to treat for an additional harmful outcome of 556 patients at six months (that is, 18 more amputations per 10 ...

    How much does Invokana lower A1c? ›

    Patients with A1c <7% increased from 15% to 31%. In addition, Invokana demonstrated a reduction in A1c from 8.3% to 7.6% (P<0.001). Invokana is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

    Does Invokana have a black box warning? ›

    In 2017, the FDA used data from the CANVAS and CANVAS-R clinical trials to evaluate amputation risk. In those trials, patients using Invokana appeared to have twice the amputation risk of those receiving placebo. As such, the FDA added its most serious warning, the black box warning, to the Invokana label.

    Can canagliflozin cause pancreatitis? ›

    PANCREATITIS AND SGLT2 INHIBITOR-ASSOCIATED KETOACIDOSIS

    Reports of ketoacidosis have been identified in patients receiving SGLT2i, including canagliflozin.

    Can Invokana cause pancreatitis? ›

    The diuretic property of Invokana places a great deal of strain on your kidneys, liver and pancreas. An excessive work load can have an impact on your kidneys, ultimately resulting in infections or sudden kidney failure. Acute pancreatitis.

    Does Invokana cause joint pain? ›

    No, Invokana isn't known to cause joint or muscle pain. These weren't reported side effects in studies of Invokana. Joint and muscle pain can be side effects of other medications you may be taking. Joint pain may be caused by a type of diabetes drug called a DPP-4 inhibitor.

    Is canagliflozin a diuretic? ›

    FDA's Medical Review referred to these subgroups and to the AEs associated with these subgroups, writing, “Because canagliflozin increases urinary glucose excretion, it acts as an osmotic diuretic with an increase in urine output, and there was an increased incidence of adverse events related to intravascular volume ...

    Does Invokana cause kidney stones? ›

    Specifically, Invokana problems involved dehydration, kidney failure, kidney impairment or problems with kidney stones, hypersensitivity, urinary tract infections, and abnormal weight loss.

    Is canagliflozin the same as metformin? ›

    Canagliflozin works in the kidneys to prevent absorption of glucose (blood sugar). This helps lower the blood sugar level. Metformin reduces the absorption of sugar from the stomach, reduces the release of stored sugar from the liver, and helps your body use sugar better.

    What is the safest diabetic medicine on the market? ›

    Official answer. Most experts consider metformin to be the safest medicine for type 2 diabetes because it has been used for many decades, is effective, affordable, and safe. Metformin is recommended as a first-line treatment for type 2 diabetes by the American Diabetes Association (ADA).

    Which is safer Farxiga or Invokana? ›

    Is Farxiga Worse Than Invokana? Farxiga (sold under the brand name Forxiga outside the United States), appears to have all the same adverse side effects as Invokana, however Farxiga has also been found to increase LDL cholesterol (the “bad” cholesterol).

    What is the most prescribed medication for diabetes? ›

    Insulin. Insulin is the most common type of medication used in type 1 diabetes treatment.

    Does Invokana make you hungry? ›

    A study found people who lost weight with the Type 2 diabetes drug Invokana (canagliflozin) got hungrier and ate more, leading to a weight loss plateau.

    How much weight can you lose on Invokana? ›

    Invokana led to weight loss whether taken alone or in combination with common diabetes medications, including metformin and sulfonylureas. Studies show that people taking the 300 mg dose alone or with other diabetes drugs may lose about 6-9 pounds over six months.

    Is there a substitute for Invokana? ›

    Just like Invokana, Farxiga and Jardiance are two SGLT2 inhibitors used to control blood sugar in those with type 2 diabetes.

    Can canagliflozin cause kidney problems? ›

    In addition to acute kidney injury, some other possible side effects of canagliflozin or dapagliflozin include low blood pressure, a condition of too much acid in the blood called ketoacidosis, serious urinary tract infections, and yeast infections.

    Can canagliflozin cause constipation? ›

    Increased likelihood of urinary tract infections. Increased need to visit the toilet ( polyuria ) Constipation. Nausea.

    What happens when you stop taking Invokana? ›

    Will stopping my Invokana treatment cause any side effects? No, stopping Invokana treatment doesn't cause any side effects. But without treatment, your blood sugar levels may go up. You shouldn't stop taking Invokana unless your doctor recommends it.

    Does Invokana lower A1C? ›

    Invokana is classified as an SGLT-2 (sodium-glucose co-transporter-2) inhibitor. It blocks proteins in the kidney that reabsorb sugar (glucose) back into the bloodstream which results in more glucose being excreted in the urine. This helps to lower blood sugar and improve A1C.

    Videos

    1. 7 Farxiga Side Effects You Should Not Ignore | Farxiga (Dapagliflozin) For Diabetes
    (Pharmacist Conversations)
    2. How does Dapagliflozin work? Understanding SGLT2 inhibitors.
    (Zero To Finals)
    3. What To Avoid When Taking Metformin | Drug Interactions | Pharmacology
    (JJ Medicine)
    4. Jardiance (empagliflozin) | Jardiance Side Effects, Precautions, FDA Warning
    (Pharmacy Update)
    5. Professor David Wheeler - Renoprotective effects of SGLT2 inhibitors
    (At the Limits - Leading Medical Education)
    6. Role of Empagliflozin (SGLT2 inhibitor) beyond glycaemic control 2/2
    (Medurstand)
    Top Articles
    Latest Posts
    Article information

    Author: Arline Emard IV

    Last Updated: 11/11/2022

    Views: 6598

    Rating: 4.1 / 5 (52 voted)

    Reviews: 83% of readers found this page helpful

    Author information

    Name: Arline Emard IV

    Birthday: 1996-07-10

    Address: 8912 Hintz Shore, West Louie, AZ 69363-0747

    Phone: +13454700762376

    Job: Administration Technician

    Hobby: Paintball, Horseback riding, Cycling, Running, Macrame, Playing musical instruments, Soapmaking

    Introduction: My name is Arline Emard IV, I am a cheerful, gorgeous, colorful, joyous, excited, super, inquisitive person who loves writing and wants to share my knowledge and understanding with you.